Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

This review provides an overview of recent experience in the field of resistance to tyrosine kinase inhibitors (TKI) on lung cancer, focusing on results from preclinical resistance models and studies of patient-derived, TKI-resistant tumor specimens.